Zevra Therapeutics Swings to Q3 2026 Net Income of $19.21 Million

Bitget2026/11/03 21:07

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Zevra Therapeutics swung to net income of $19.2 million in Q3 2026 from a year-earlier loss of $544,000.
Net revenue rose 45% year over year to $37.8 million, including $34 million from MIPLYFFA.
Cash, cash equivalents and investments totaled $270.9 million at September 30, 2026.
The Phase 3 celiprolol trial enrolled six patients during the quarter, bringing total enrollment to 72.
A supplemental application for MIPLYFFA in infants younger than 24 months is expected in Q1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zevra Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611031605PRIMZONEFULLFEED9869440) on November 03, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Zevra Therapeutics Swings to Q3 2026 Net Income of $19.21 Million

You may also like

Crypto prices